Generic competition has cut deeply into the sales of the child asthma drug Orapred, forcing BioMarin to cut its sales projections and hand pink slips to 52 members of its sales force. The sales forecast for the drug was cut to $8 million to $10 million, from $15 million to $20 million. "In the last several weeks generic competition to Orapred has intensified and the Orapred market share has continued to erode," the Swiss company's CEO, Jean-Jacques Bienaime, said in a statement.
- read this article from the San Francisco Business Times for more